Computational Analysis of *Spilanthes acmella* Secondary Metabolites: A Swiss ADME Study

Pushpak S. Bari., Rahul S. Adnaik., Omkar J. Yadav

Dept. Of Pharmacology, Anandi Pharmacy College, Kalambe Tarf Kale Pin 416205 Maharashtra, India.

ABSTRACT

The plants are utilized for therapeutic benefits in various diseases. The interest in the analysis of conventional medicinal plants has grown significantly on a global scale in recent years. As the field of computer mechanics developed, in silico techniques like network analysis and the pharmacological basis of commonly used medicinal herbs actions are developed. In this technique, pharmacokinetic screening, in silico screening, and network pharmacology have been utilized to explain the method in which medicinal plants work. Even before in vivo and in vitro testing begin, the majority of candidate compounds with unwanted features can be sorted out through the use of in silico studies in the early phases of drug development. *Spilanthes acmella* is known for its traditional medicinal applications. *Spilanthes acmella* has a long record of use as a spice, antimicrobial, antifungal, and antimalarial, as well as a treatment for TB, flu, cough, toothache, and rabies. Therefore, the present study focuses on the application of the in silico Swiss ADME device for the Pharmacological features of *Spilanthes acmella*. Researchers can use the findings of these studies for additional in vitro and in vivo investigations to find the pharmacological basis of traditional medicinal plants.

Keywords: Swiss ADME, Medicinal plant, pharmacological properties, phytochemicals, *Spilanthes acmella*.

1. INTRODUCTION:

With a wealth of therapeutic and medicinal elements, *Spilanthes acmella* is an important plant for medicine that occurs over the world's tropical and subtropical climates. The main components, "spilanthol" and "acmellonate," can cause sweating and are sometimes administered to reduce toothache pain. Treatment of rheumatism, sialagogue for stammering, tongue paralysis, antipyretic, sore throat, and gum infections are some of the other significant traditional applications of this herb [1]. *Spilanthes acmella* has a long tradition of use as a spice, antiseptic, antifungal, and antimalarial. It is also used as a treatment for rabies, TB, cough, toothache, and flu. Common uses include antibacterial and anti-inflammatory properties. Over the past 50 years, it has lots of health benefits due to its bioactive components. Traditional medicines have become more and more popular **[2]**. It belongs to the "Asteraceae" family, containing alkyl amides, Alkyl amides have significant biological activities, including pharmacological effects. Supercritical fluid extraction (SFE) enhances bioactive compound recovery **[3,4]**. The plant is known for its traditional medicinal applications, Although While this herb is native to Brazil, it is particularly popular in Borneo, Malaya, Africa, India, Sri Lanka, North Australia, and America. The flower heads have the strongest flavor, with a tingling, itching, numbing, and salivary sensation, although the entire plant is poorly bitter **[5]**. One of the most important and critical problems facing current pharmaceutical science is the development of new, highly safe, and effective treatments. The primary obstacles to current pharmaceutical research and development are their high cost **[6,7]**.Billions of dollars must be invested by large drug companies on new medication research projects. These efforts often have very little chance of success, and there is very little possibility that the created medication will reach the pharmaceutical sector and make a profit **[6,8]**. In the pharmaceutical sector, finding a balance between risk and reward has been and continues to be a significant challenge **[8]**. Safety and efficacy issues, which are in part caused by toxic (side) effects and absorption, distribution, metabolism, and excretion (ADME) features, usually correspond to a new drug's ability of entering the pharmaceutical market**[9,10]**. Even before in vivo and in vitro testing start, the majority of candidate compounds with undesirable characteristics can be sorted out through the use of in silico inquiries in the initial stages of drug development.**[11,12]**. In addition to save the lives of millions of lab animals, this may significantly cut down on work, time, and money costs. This work's primary objective is a thorough in silico evaluation of Salubrinal's and other structural analogues' ADME features **[13,14]**.

2. Materials and Methods

2.1. Swiss ADME:

To determine the individual ADME behaviors of the compounds from the Swiss Institute of Bioscience (http://www.sib.swiss), the Swiss ADME system (www.swissadme.ch) was accessed utilizing a web server that shows the Swiss ADME Submission page in Google *Spilanthes acmella*. The simple molecular input line entry system (SMILES) defines the list, which has several inputs with one input molecule per line. The results are displayed for each molecule in tables, graphs, and an Excel spreadsheet *(Egan et al.,* 2000)*[15].*

2.2. Structure and bioavailability radar:

Using classical SMILES, the first part showed the two-dimensional chemical structure. The bioavailability sensor provides a first assessment of the similarity to drugs of the drugs of interest. The ideal physicochemical area the pink area represents each feature that is anticipated to be orally bioavailable. There are six physicochemical properties taken into account. Specifically, LIPO means lipophilicity, SIZE for size, POLAR for polarity, INSOLU for insolubility, INSATU for insaturation, and FLEX for flexibility. Size: MW between 150 and 500 g/mol, polarity: TPSA between 20 and 130 0A2, solubility: log S not greater than 6, saturation: fraction of carbons in the hybridization of sp3 not less than 0.25, flexibility: no more than 9 rotatable bonds, and lipophilicity: XLOGP3 between 0.7 and + 5.0*(Daina et al., 2017)[16].*

2.3. Physicochemical properties:

This section involves clean molecular and physicochemical properties like molar refractivity, TPSA, fraction csp3, number of rotatable bonds, number of H-bond supporters, number of H-bond donors, molecular weight, number of heavy atoms, number of aromatic heavy atoms, and molar refractivity. The values were obtained using Open Babel version 2.3.0.*(Daina et al., 2017 & O'Boyle, 2011)[16,17].*

2.4. Lipophilicity:

One of the most important factors in medication design and discovery is lipophilicity. *(Leeson & Springthorpe, 2007)[18]* due to the fact that it improves medicinal chemistry's most useful and educational physicochemical property.*(Testa et al., 2000)[19].* It can be shown directly as distribution coefficients (log D) or Partition coefficients (log P) represent the partitioning behavior of a non-ionized solute in a system comprising water and an immiscible organic solvent, as indicated by log P*[20].* An increased affinity for lipophilic environments is associated with elevated log P values. *(Arnott & Planey, 2012)[21].* Swiss ADME offers five publicly available models—XLOGP3, WLOGP, MLOGP, SILICOS-IT, and iLOGP—to analyze a compound's lipophilicity of character. XLOGP3, a structure involving a knowledge-based library and correction factors *(Cheng, 2007)[22],* WLOGP is the use of a fragmental system with a totally atomic strategy.*(Wildman and Crippen, 1999)[23].* Using 13 chemical descriptors, MLOGP, a precursor of the topological approach, suggested a linear relationship. *(Moriguchi et al., 1992 & Moriguchi et al., 1994)[24,25]* iLOGP, a physics-based technique utilizing the generalized-born and surface area of solvents (GB/SA) model to determine the free energies of solvation in n-octanol and water; SILICOS-IT, a mongrel technique that uses 7 topological descriptors & 27 pieces; The consensus log P o/w is the average of the numbers of the values predicted by the five proposed methods.*(Daina et al, 2017)[26].*

2.5. Solubility:

The pressure, temperature, and the solvent used each have an important effect on a compound's bioavailability. The level of stability at which adding extra solute does not increase the amount present in the solution is known as the saturation concentration. *(Lachman et al., 1986 & Savjani et al., 2012)[27].* When a drug's maximum dose strength dissolves in 250 milliliters or less of water-based solution with a pH between 1 and 7.5, it is said to be extremely soluble. Swiss ADME includes two geometric methods for estimating water solubility. The first is the use of the ESOL model (Solubility class: Insoluble<-10 poorly<-6, moderately<-4 soluble<-2 very<0<-10 poorly<-6, moderately<-4 soluble<-2very<0<-10 poorly<-6, and moderately<-4 soluble<-2 very<0 are the specifications for the Log S Scale.

2.6. Pharmacokinetics:

The border is found in an area with good qualities for GI absorption on a plot of two identified descriptors, ALOGP and PSA, respectively. The Egan egg, which is used to evaluate the predicted power of the model for GI passive absorption and predictions for brain access by passive diffusion, is an elliptical region that is most populated by well-absorbed molecules. Finally, the BOILED-Egg (Brain or Intestina L Estimate D permeation predictive model) is laid. The BOILED-Egg model offers a fast,

spontaneous, efficient, and noisy technique for predicting passive GI absorption that is helpful for drug design and discovery.*(Di et al., 2012 & Brito-Sanchez et al., 2015)[28].* CYP isoenzymes biotransform within 50–90% of pharmaceutical substances from CYP's five major variants: CYP1A2, CYP3A4, CYP2C9, CYP2C19, and CYP2D6. P-gp, which is widely distributed and found in the intestinal epithelium, transports antibiotics from the brain's capillary endothelial cells back into the capillaries and back into the intestinal lumen. *(Ogu & Maxa, 2000 and Ndombera et al., 2019)[29,30].* With a 10 fold CV of ACC=0.72/AUC=0.77 and an external ACC=0.88/AUC=0.94 for the P-gp substrate, the SVM model was created on 1033 compounds (training set) and analyzed on 415 molecules (test set). With a 10-fold CV of ACC=0.83/AUC=0.90 and an external ACC=0.84/AUC=0.91, the SVM model for the Cytochrome P-450 1A2 inhibitor molecule was generated using 9145 molecules (training set) and analyzed on 3000 molecules (test set). With a 10 fold CV of ACC=0.80/AUC=0.86 and an external ACC=0.80/AUC=0.87, the SVM model for the Cytochrome P-450 2C19 inhibitor molecule was constructed on 9272 molecules (training set) and evaluated on 3000 molecules (test set). The SVM model for the Cytochrome P-450 2C9 inhibitor chemical was created on 5940 molecules (training set) and assessed on 2075 molecules (test set) with a 10-fold CV of ACC=0.78/AUC=0.85 and an external ACC=0.71/AUC=0.81.

The SVM model for the Cytochrome P-450 2D6 inhibitor molecule was created using 3664 molecules (training set) and analyzed on 1068 molecules (test set), with a 10-fold CV of ACC=0.79/AUC=0.85 and an outside ACC=0.81/AUC=0.87. The SVM model for the Cytochrome P-450 3A4 inhibitor compound was developed on 7518 molecules (training set) and verified on 2579 molecules (test set) with a 10-fold CV of ACC=0.77/AUC=0.85 and an external ACC=0.78/AUC=0.86.

2.7. Medicinal chemistry:

The objective of these sections is for helping medical pharmacists in their continuous search for new medicines. The molecules known as PAINS (Pan Assay Interference Compounds, frequent hitters, or promiscuous compounds) exhibit strong reactions in assays regardless of the protein targets; in particular, these compounds are said to be active in a wide range of assays, which may serve as possible options for additional research. If the compound contains such units under evaluation, Swiss ADME issues a warning.*(Baell & Holloway, 2010)[31].* In high throughput screening (HTS), the idea of lead likeness is intended to create leads with extraordinary affinity, enabling the exploitation of extra interactions during the lead optimization stage. Chemical changes to leads are expected to lower their size and enhance their lipophilicity, making them less hydrophobic than compounds that match drugs. The optimization of lead has been performed using a rule-based methodology with molecules ranging in molecular weight from 100 to 350 Da and C log P from 1 to 3.0. Many people believe that these molecules are better than those of drug-like compounds and, thus, lead-like *(Hann & Keseru, 2012 Teague et al., 1999)[32,33].*


Figure 1: Model of the Phytoconstituents in Boiled Eggs of *Spilanthes acmella.*

3. Result

Table 1: General Characteristics of Phytoconstituents of *Spilanthes acmella*.

Sr. No	Small molecule	Pub chem ID	Molecular formula	Canonical SMILES	Molecular weight (in g/mol)
1	Phenalics	996	C6H6O	C1=CC=C(C=C1)O	94.11
2	coumarin	323	C9H6O2	C1=CC=C2C(=C1)C=CC(=O)O2	146.14
3	Triterpenoid	4516774	C30H48O7S	C[C@]12CC[C@@H]([C@@]([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C)COS(=O)(=O)O)O	552.8
4	Sitostenone	5484202	C29H48O	CC[C@H](CC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(C)C	412.7
5	2E,6E,8E-decatrienoic acid	5312367	C10H14O2	C/C=C/C=C/CC/C=C/C(=O)O	166.22
6	Isobutyramide	68424	C4H9NO	CC(C)C(=O)N	87.12
7	Stearic acid	5281	C18H36O2	CCCCCCCCCCCCCCCCCC(=O)O	284.5
8	n-Hexadecanoic acid	985	C16H32O2	CCCCCCCCCCCCCCCC(=O)O	256.42
9	Tetradecanoic acid	11005	C14H28O2	CCCCCCCCCCCCCC(=O)O	228.37
10	3-Carene	26049	C10H16	CC1=CCC2C(C1)C2(C)C	136.23
11	Steroids	139082353	C26H44N2O	C[C@H]([C@@H]1CC[C@H]2[C@]1(CC[C@@H]3[C@@H]2CC=C4[C@]3(CC[C@@H](C4)N(C)C)C)C)N(C)C(=O)C	400.6
12	Alpha-caryophyllene	5281520	C15H24	C/C/1=C\CC(/C=C/C/C(=C/CC1)/C)(C)C	204.35
13	Thymol	6989	C10H14O	CC1=CC(=C(C=C1)C(C)C)O	150.22
14	Germacrene D	5317570	C15H24	C/C/1=C\CCC(=C)/C=C/[C@@H](CC1)C(C)C	204.35
15	triterpenoid	451674	C30H48O7S	C[C@]12CC[C@@H]([C@@]([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C)COS(=O)(=O)O)O	552.8
16	Glycoside	637579	C29H44O12	C[C@@H]1[C@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@@H]([C@@]3([C@@H]4[C@@H](CC[C@]3(C2)O)[C@@]5(CC[C@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O	584.7
17	Anthraquinone	6780	C14H8O2	C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3C2=O	208.21
18	Iridoid	453214	C20H24O12	COC(=O)C1=CO[C@H]([C@H]2[C@@H]1C=C[C@@]23C=C(C(=O)O3)CO)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O	456.4
19	proline	145742	C5H9NO2	C1C[C@H](NC1)C(=O)O	115.13
20	Lycopene	446925	C40H56	CC(=CCC/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C/C=C(/CCC=C(C)C)\C)\C)\C)/C)/C)/C)/C	536.9
21	Estragole	8815	C10H12O	COC1=CC=C(C=C1)CC=C	148.2
22	p-Cymene	7463	C10H14	CC1=CC=C(C=C1)C(C)C	134.22
23	alpha-Pinene	6654	C10H16	CC1=CCC2CC1C2(C)C	136.23
24	3-Carene	26049	C10H16	CC1=CCC2C(C1)C2(C)C	136.23
25	Palmitic acid	985	C16H32O2	CCCCCCCCCCCCCCCC(=O)O	256.42

Table 2: Lipophilicity of the Phytoconstituents of *Spilanthes acmella*.

Sr. No.	Small molecule	Ilogp	XLOGP3	WLOGP	MLOGP	SILICOS-IT	Consensus Log $P_{0/w}$
1	Phenalics	1.24	1.46	1.39	1.45	1.50	1.41
2	coumarin	1.75	1.39	1.79	1.65	2.50	1.82
3	Triterpenoid	2.97	5.88	7.11	4.37	3.64	4.80
4	Sitostenone	4.99	9.30	8.23	6.62	7.63	7.36
5	2E,6E,8E-decatrienoic acid	2.30	2.49	2.54	2.29	2.09	2.34
6	Isobutyramide	1.04	0.18	0.13	0.08	-0.28	0.23
7	Stearic acid	4.30	8.23	6.33	4.67	6.13	5.93
8	n-Hexadecanoic acid	3.85	7.17	5.55	4.19	5.15	5.20
9	Tetradecanoic acid	3.32	6.11	4.77	3.69	4.37	4.45
10	3-Carene	2.63	4.38	3.00	4.29	2.79	3.42
11	Steroids	4.37	5.26	5.36	4.63	3.87	4.70
12	Alpha-caryophyllene	3.29	4.55	5.04	4.53	3.91	4.26
13	Thymol	2.32	3.30	2.82	2.76	2.79	2.80
14	Germacrene D	3.31	4.74	4.89	4.53	4.01	4.30
15	triterpenoid	2.97	5.88	7.11	4.37	3.64	4.80
16	Glycoside	3.18	-1.70	-1.51	-1.11	-0.97	-0.42
17	Anthraquinone	1.94	3.39	2.46	1.86	3.56	2.64
18	Iridoid	2.14	-1.61	-2.77	-2.04	-2.31	-1.32
19	proline	0.84	-2.50	-0.56	-2.59	0.22	-0.92
20	Lycopene	-	-	12.94	-	-	-
21	Estragole	2.47	3.37	2.42	2.67	2.96	2.78
22	p-Cymene	2.51	4.10	3.12	4.47	3.29	3.50
23	alpha-Pinene	2.63	4.48	3.00	4.29	2.79	3.44
24	3-Carene	2.63	4.38	3.00	4.29	2.79	3.42
25	Palmitic acid	3.85	7.17	5.55	4.19	5.25	5.20

Table 3: Water solubility of the phytoconstituents of *Spilanthes acmella*.

Small molecule	ESOL				Ali				SILICOS-IT			
	LogS (ESOL)	Solubility		Class	Log S (ESOL)	Solubility		Class	Log S (ESO)	Solubility		Class
		mg/mL	mol/L			mg/mL	mol/L			mg/mL	mol/L	
Phenalics	-1.98	9.91e-01	1.05e-02	Very soluble	-1.49	3.04e+00	3.23e-02	Very soluble	-1.73	1.74e+00	1.85e-02	Soluble
coumarin	-2.29	7.42e-01	5.08e-03	soluble	-1.63	3.44e+00	2.35e-0.2	Very soluble	-3.59	3.77e-02	2.58e-04	Soluble
Triterpenoid	-6.71	1.08e-04	1.96e-07	Poorly soluble	-8.37	2.34e-06	4.24e-09	Poorly soluble	-5.12	4.18e-03	7.57e-06	Moderately Soluble
Sitostenone	-7.86	5.67e-06	1.38e-08	Poorly soluble	-6.88	5.39e-05	1.31e-07	Very soluble	-0.82	1.76e+01	1.50e-01	Soluble
2E,6E,8E-decatrienoic acid	-2.11	1.29e+00	7.78e-03	soluble	-2.92	2.01e-01	1.21e-03	soluble	-0.71	3.23e+01	1.94e-01	Soluble
Isobutyramide	-0.43	3.26e+01	3.74e-01	Very soluble	-0.64	1.98e+01	2.28e-01	Very soluble	-0.19	5.64e+01	6.47e-01	soluble
Stearic acid	-5.73	5.26e-04	1.85e-06	Moderately soluble	-8.87	3.80e-07	1.33e-09	Poorly Soluble	-6.11	2.19e-04	7.71e-07	Poorly Soluble
n-Hexadecanoic acid	-5.02	2.43e-03	9.49e-06	Moderately soluble	-7.77	4.31e-06	1.68e-08	Poorly soluble	-5.31	1.25e-03	4.88e-06	Moderately soluble
Tetradecanoic acid	-5.37	1.15e-03	4.25e-06	Moderately Soluble	-8.31	1.31e-06	4.85e-09	Poorly Soluble	-5.71	5.24e-04	1.94e-06	Moderately Soluble

Molecule											
3-Carene	-3.44	4.90e-02	3.60e-04	Soluble	-4.10	1.09e-02	8.01e-05	Moderately soluble	-2.23	8.06e-01	5.92e-03	Soluble
Steroids	-5.37	1.69e-03	4.23e-06	Moderately Soluble	-5.50	1.26e-03	3.13e-06	Moderately soluble	-4.47	1.35e-02	3.37e-05	Moderately Soluble
Alpha-caryophyllene	-3.97	2.17e-02	1.06e-04	Soluble	-4.27	1.09e-02	5.34e-05	Moderately soluble	-3.52	6.19e-02	3.03e-04	Soluble
Thymol	-3.19	9.74e-02	6.49e-04	soluble	-3.40	5.97e-02	3.98e-04	soluble	-3.01	1.46e-01	9.71e-04	Soluble
Germacrene D	-4.03	1.92e-02	9.39e-05	Moderately soluble	-4.47	6.93e-03	3.39e-05	Moderately soluble	-3.32	9.83e-02	4.81e-04	Soluble
triterpenoid	-6.71	108e-04	1.96e-07	Poorly soluble	-8.37	2.34e-06	4.24e-09	Poorly soluble	-5.12	4.18e-03	7.57e-06	Moderately Soluble
Glycoside	-2.13	4.34e+00	7.42e-03	soluble	-2.13	4.38e+00	7.49e-03	soluble	0.33	1.25e+03	2.13e+00	soluble
Anthraquinone	-3.82	3.14e-02	1.51e-04	soluble	-3.79	3.41e-02	1.64e-04	soluble	-5.25	1.17e-03	5.64e-06	Moderately soluble
Iridoid	-1.26	2.51e+01	5.50e-02	Very soluble	-1.69	9.30e+00	2.04e-02	Very soluble	1.77	2.71e+04	5.94e+01	soluble
proline	1.09	1.41e+03	1.22e+01	Highly soluble	2.01	1.17e+04	1.02e+02	Highly soluble	-0.13	8.57e+01	7.45e-01	soluble
Lycopene											
Estragole	-3.09	1.21e-01	8.17e-04	soluble	-3.24	8.49e-02	5.73e-04	soluble	-3.35	6.54e-02	4.42e-04	soluble
p-Cymene	-3.63	3.12e-02	2.33e-04	Soluble	-3.81	2.10e-02	1.56e-04	Soluble	-3.57	3.58e-02	2.67e-04	Soluble
alpha-Pinene	-3.51	4.24e-02	3.11e-04	soluble	-4.20	8.59e-03	6.31e-05	Moderately soluble	-2.23	8.06e-01	5.92e-03	Soluble
3-Carene	-3.44	4.90e-02	3.60e-04	soluble	-4.10	1.09e-02	8.01e-05	Moderately soluble	-2.23	8.06e-01	5.92e-03	Soluble
Palmitic acid	-5.02	2.43e-03	9.49e-06	Moderately soluble	-7.77	4.31e-06	1.68e-08	Poorly soluble	-5.31	1.25e-03	4.88e-06	Moderately soluble

Table 4: Pharmacokinetic Parameters of the Phytoconstituents of *Spilanthes acmella*.

Molecules	GI absorption	BBB permeant	P-Gp substrate	CYP1A2 inhibitor	CYP2C19 inhibitor	CYP2C9 inhibitor	CYP2D6 inhibitor	CYP3A4 inhibitor	Log Kp (cm/s)
Phenalics	High	Yes	No	Yes	No	No	No	No	-5.84 cm/s
coumarin	High	Yes	No	Yes	No	No	No	No	-6.20cm/s
Triterpenoid	Low	No	Yes	No	No	No	No	No	-5.50cm/s
Sitostenone	Low	No	No	No	No	No	No	No	-2.21 cm/s
2E,6E,8E-decatrienoic acid	High	Yes	No	No	No	No	No	No	-5.55cm/s
Isobutyramide	High	No	No	No	No	No	No	No	-6.70cm/s
Stearic acid	High	No	No	Yes	No	No	No	No	-2.19cm/s
n-Hexadecanoic acid	High	Yes	No	Yes	No	Yes	No	No	-2.77cm/s
Tetradecanoic acid	High	Yes	No	Yes	No	Yes	No	No	-2.49cm/s
3-Carene	Low	Yes	No	No	No	Yes	No	No	-4.02cm/s
Steroids	High	Yes	No	No	No	No	Yes	No	-5.01cm/s
Alpha-caryophyllene	Low	No	No	No	No	Yes	No	No	-4.32cm/s
Thymol	High	Yes	No	Yes	No	No	No	No	-4.87cm/s
Germacrene D	Low	No	No	No	No	Yes	No	No	-4.18cm/s

triterpenoid	Low	No	Yes	No	No	No	No	No	-5.50cm/s
Glycoside	Low	No	No	No	No	No	No	No	-11.07cm/s
Anthraquinone	High	Yes	No	Yes	Yes	No	No	No	-5.16cm/s
Iridoid	Low	No	No	No	No	No	No	No	-10.23cm/s
proline	High	No	No	No	No	No	No	No	-8.78cm/s
Lycopene	-	-	-	-	-	-	-	-	-
Estragole	High	Yes	No	Yes	No	No	No	No	-4.81cm/s
p-Cymene	Low	Yes	No	No	No	No	Yes	No	-4.21cm/s
alpha-Pinene	Low	Yes	No	No	No	Yes	No	No	-3.95cm/s
3-Carene	Low	Yes	No	No	No	Yes	No	No	-4.02cm/s
Palmitic acid	High	Yes	No	Yes	No	Yes	No	No	-2.77cm/s

Table 5: Drug likeness of the Phytoconstituents of *Spilanthes acmella.*

Molecules	Lipinski	Ghose	Veber	Egan	Muegge	Bioavailability score
Phenalics	Yes, 0 violation	No; 3 violations: MW<160, MR<40, #atoms<20	Yes	Yes	No; 2 violations: MW<200, Heteroatoms<2	0.55
coumarin	Yes, 0 violation	No: 2 violation, MW<160,#atoms<20	Yes	Yes	No, 1 violation, MW<200	0.55
Triterpenoid	No;2 violation:MW>500 MLOGP>4.15	No; 4 violations: MW>480, WLOGP>5.6, MR>130, #atoms>70	Yes	No; 1 violation: WLOGP>5.88	No; 1 violation: XLOGP3>5	0.56
Sitostenone	Yes; 1 violation: MLOGP>4.15	No; 3 violations: WLOGP>5.6, MR>130, #atoms>70	Yes	No; 1 violation: WLOGP>5.88	No; 2 violations: XLOGP3>5, Heteroatoms<2	0.55
2E,6E,8E-decatrienoic acid	Yes; 0 violation	Yes	Yes	Yes	No, 1 violation, MW<200	0.85
Isobutyramide	Yes; 0 violation	No; 3 violations: MW<160, MR<40, #atoms<20	Yes	Yes	No; 2 violations: MW<200, #C<5	0.55
Stearic acid	Yes; 1 violation: MLOGP>4.15	No; 1 violation: WLOGP>5.6	No; 1 violation: Rotors>10	No; 1 violation: WLOGP>5.88	No; 2 violations: XLOGP3>5, Rotors>15	0.85
n-Hexadecanoic acid	Yes; 1 violation: MLOGP>4.15	Yes	No; 1 violation: Rotors>10	Yes	No; 1 violation: XLOGP3>5	0.85
Tetradecanoic acid	Yes; 1 violation: MLOGP>4.15	No; 1 violation: WLOGP>5.6	No; 1 violation: Rotors>10	No; 1violation:WLOGP>5.88	No; 1 violation: XLOGP3>5	0.85
3-Carene	Yes; 1 violation: MLOGP>4.15	No; 1 violation: MW<160	Yes	Yes	No; 2 violations: MW<200,Heteroatoms<2	0.55
Steroids	Yes; 1 violation: MLOGP>4.15	No; 1 violation: #atoms>70	Yes	Yes	No; 1 violation: XLOGP3>5	0.55
Alpha-caryophyllene	Yes; 1 violation: MLOGP>4.15	Yes	Yes	Yes	No; 1 violation: Heteroatoms<2	0.55
Thymol	Yes; 0 violation	No; 1 violation: MW<160	Yes	Yes	No; 2 violations: MW<200,	0.55

					Heteroatoms<2	
Germacrene D	Yes; 1 violation: MLOGP>4.15	Yes	Yes	Yes	No; 1 violation: Heteroatoms<2	0.55
triterpenoid	No; 2 violations: MW>500, MLOGP>4.15	No; 4 violations: MW>480, WLOGP>5.6, MR>130, #atoms>70	Yes	No; 1 violation:WLOGP>5.88	No; 1 violation: XLOGP3>5	0.56
Glycoside	No; 3 violations: MW>500, NorO>10, NHorOH>5	No; 4 violations: MW>480, WLOGP<-0.4, MR>130, #atoms>70	No; 1 violation: TPSA>140	No; 1 violation: TPSA>131.6	No; 3 violations: TPSA>150, H-acc>10, H-don>5	0.17
Anthraquinone	Yes; 0 violation	Yes	Yes	Yes	Yes	0.55
Iridoid	Yes; 1 violation: NorO>10	No; 1 violation: WLOGP<-0.4	No; 1 violation: TPSA>140	No; 1 violation: TPSA>131.6	No; 2 violations: TPSA>150, H-acc>10	0.11
Proline	Yes; 0 violation	No; 4 violations: MW<160, WLOGP<-0.4, MR<40, #atoms<20	Yes	Yes	No; 2 violations: MW<200, XLOGP3<-2	0.55
Lycopene	violation					
Estragole	Yes; 0 violation	No; 1 violation: MW<160	Yes	Yes	No; 2 violations: MW<200, Heteroatoms<2	0.55
p-Cymene	Yes; 1 violation: MLOGP>4.15	No; 1 violation: MW<160	Yes	Yes	No; 2 violations: MW<200, Heteroatoms<2	0.55
alpha-Pinene	Yes; 1 violation: MLOGP>4.15	No; 1 violation: MW<160	Yes	Yes	No; 2 violations: MW<200, Heteroatoms<2	0.55
3-Carene	Yes; 1 violation: MLOGP>4.15	No; 1 violation: MW<160	Yes	Yes	No; 2 violations: MW<200, Heteroatoms<2	0.55
Palmitic acid	Yes; 1 violation: MLOGP>4.15	Yes	No; 1 violation: Rotors>10	Yes	No; 1 violation: XLOGP3>5	0.85

Table 6: Medicinal Chemistry Properties of Phytoconstituents of *Spilanthes acmella*.

Molecules	Pains	Brenk	Leadlikeness	Synthetic accessibility
Phenalics	0 alert	0 alert	No, 1 violation, MW<250	1.00
coumarin	0 alert	1 alert :cumarine	No, 1 violation, MW<250	2.74
Triterpenoid	0 alert	2 alerts: isolated_alkene, sulfonic_acid_2	No; 2 violations: MW>350, XLOGP3>3.5	6.65
Sitostenone	0 alert	0 alert	No; 2 violations: MW>350, XLOGP3>3.5	6.11
2E,6E,8E-decatrienoic acid	0 alert	2alerts:michael_acceptor_1, polyene	No, 1 violation, MW<250	2.93
Isobutyramide	0 alert	0 alert	No, 1 violation, MW<250	1.00
Stearic acid	0 alert	0 alert	No; 2 violations: Rotors>7, XLOGP3>3.5	2.54
n-Hexadecanoic acid	0 alert	0 alert	No; 2 violations: Rotors>7, XLOGP3>3.5	2.31
Tetradecanoic acid	0 alert	0 alert	No; 2 violations: Rotors>7, XLOGP3>3.5	2.42
3-Carene	0 alert	1 alert: isolated_alkene	No; 2 violations: MW<250, XLOGP3>3.5	3.84
Steroids	0 alert,	1 alert: isolated_alkene	No; 2 violations: MW>350, XLOGP3>3.5	5.47
Alpha-caryophyllene	0 alert	1 alert: isolated_alkene	No; 2 violations: MW<250, XLOGP3>3.5	3.66
Thymol	0 alert	0 alert	No; 1 violation: MW<250	1.00
Germacrene D	0 alert	1 alert: isolated_alkene	No; 2 violations: MW<250, XLOGP3>3.5	4.55
triterpenoid	0 alert	2 alerts: isolated_alkene, sulfonic_acid_2	No; 2 violations: MW>350, XLOGP3>3.5	6.65
Glycoside	0 alert	1 alert: saponine_derivative	No; 1 violation: MW>350	7.13
Anthraquinone	1 alert: quinone_A	0 alert	No; 1 violation: MW<250	2.07
Iridoid	0alert	2 alerts: isolated_alkene, more_than_2_esters	No; 1 violation: MW>350	6.45
proline	0 alert	0 alert	No; 1 violation: MW<250	1.54
Lycopene	0 alert	0 alert		
Estragole	0 alert	1 alert: isolated_alkene	No; 1 violation: MW<250	1.28
p-Cymene	0 alert	0 alert	No; 2 violations: MW<250, XLOGP3>3.5	1.00
alpha-Pinene	0 alert	1 alert:isolated_alkene	No; 2 violations: MW<250, XLOGP3>3.5	4.44
3-Carene	0 alert	1 alert:isolated_alkene	No; 2 violations: MW<250, XLOGP3>3.5	3.84
Palmitic acid	0 alert	0 alert	No; 2 violations: Rotors>7, XLOGP3>3.5	2.31

The lipophilicity of the monosaccharaide molecule is not as evident as that of the other 25 compounds in the test. Because it affects how substances are absorbed, transported, digested, and eliminated from the body, lipophilicity is important in drug development and pharmacokinetics.

As it impacts how chemicals react in solutions, changing reactions, transport, and bioavailability, water solubility is important in multiple fields, including chemistry, biology, and environmental science. The majority of molecules are soluble.

Studying how medicines are absorbed, transported, metabolized, and released by the body is essential for maximizing therapeutic efficacy and reducing side effects, which is why pharmacokinetics is important. The CYP1A2, CYP2C19, CYP2D6, and CYP3A4 inhibitors are the most common molecules with both high and low absorption and metabolites.

As it mixes elements from pharmacology, biology, and chemistry to create and enhance substances that can effectively cure illnesses, medicinal chemistry is essential to the creation of unique medications and treatments. The molecule with the most 0 alert pains is the majority.

In pharmaceutical development, drug similarity is essential since it contributes in determining a compound's bioavailability and therapeutic potential, facilitating researchers in choosing suitable applicants for additional testing. The majority of molecules exhibit Lipinski's rules; their bioavailability score is 0.55 and their verbs are yes.

4. Discussion:

Over 30% of every species of plant have been treated medicinally at some stage, according to the World Health Organization. *(Schippmann et al, 2002)[34].* Nowadays, multiple successful medications from natural compounds have been discovered utilizing computer-aided drug design approaches, such as the discovery of Dazamide, Imatinib, Dasatinib, and Ponatinib, among others, due to ongoing advancements in computer science*. (Ghosh AK, Gemma, 2015)[35].* These in silico methods are justified by the fact that they need significantly less time and money than classical ADMET profiling. *(DiMasi et al. 2003; Darvas et al, 2002)[36,37].*For example, it takes one minute to screen 20,000 molecules in an in silico model, while it takes 20 weeks in a "wet" laboratory. Because of the ADMET data that was gathered in the late 1990s, several pharmaceutical companies are now using computerized models, which in some cases substitute for the "wet" screens. *(Hodgson 2001)[38].* Presently available software tools frequently use quantitative structure-activity relationships, or QSAR, for determining the ADMET features of possible medications. *(Tetko et al, 2006; Hansch et al, 2004)[39,40].* In the current study, we assessed the ADME characteristics of *Spilanthes acmella* using the Swiss ADME online software program, which is freely accessible to users. Phenalics, Coumarin, Triterpenoid, Sitostenone, 2E, 6E, 8E-decatrienoic acid, Isobutyramide Stearic acid, n-Hexadecanoic acid, Tetradecanoic acid, 3-Carene, Steroids, Alpha-caryophyllene, Thymol, Germacrene D, triterpenoid, Glycoside, Anthraquinone, Iridoid, proline, Lycopene, Estragole, p-Cymene, Alpha-Pinene, and Palmitic acid are include phytoconstituents of the plants that have been determined by the software. So the phytoconstituents' ADME properties were analyzed and displayed in the relevant tables and figures. The values may be utilized as monographs by researchers and scientists to create potential synthetic and semisynthetic drugs for a range of applications.

5. Conclusion:

Given the rapid advancement of biological and chemical data, CADD has been drastically changing the research and development pathways in drug candidate generation. In terms of application, time, and cost, the use of computerized techniques in the development and discovery of drugs is well acknowledged. In these investigations, the ADME properties of phytoconstituents present in *Spilanthes acmella* plants are examined using a freely accessible web-based program called Swiss ADME.

For a greater understanding of the plant's pharmacological and biological functions, these data may be the primary tool. Even before in vivo and in vitro studies begin, the majority of candidate compounds with undesirable properties can be filtered out through the use of in silico inquiries in the beginning stages of drug development. In addition to saving the lives of millions of lab animals, this can drastically cut down on labor, time, and money demands. Researchers can use the findings of these studies to conduct additional in vitro and in real life studies to uncover the pharmacological principles of traditional medicinal herbs.

.6. References:

1. V. Sharma, J. Boonen, N. S. Chauhan, M. Thakur, B. de Spiegeleer, and V. K. Dixit, "Spilanthes acmella ethanolic flower extract: LC-MS alkylamide profiling and its effects on sexual behavior in male rats," Phytomedicine, vol. 18, no. 13, pp. 1161–1169, 2011.
2. Tyagi A, Delanty N. Herbal remedies, dietary supplements, and seizures. Epilepsia 2003;44(2):228 - 35
3. K.F. Chung, Y. Kono, C.M. Wang, C.I. Peng, Notes on Acmella (Asteraceae: Heliantheae) in Taiwan, Botanical Studies 49 (2008) 73–82.
4. Sharma UK, Pegu S. Ethnobotany of religious and supernatural beliefs of the Mising tribes of Assam with special reference to the 'Dobur Uie'. J Ethnobiol Ethnomed 2011;7:1-13
5. Rahim RA, Jayusman PA, Muhammad N. Potential antioxidant and anti-inflammatory effects of Spilanthes acmella and its health beneficial effects: A review. Int J Environ Res Public Health, 2021; 18.
6. Wouters, O.J.; McKee, M.; Luyten, J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009–2018. JAMA 2020, 323, 844–853.
7. Prasad, V.; Mailankody, S. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues after Approval. JAMA Intern. Med. 2017, 177, 1569–1575
8. . Khanna, I. Drug discovery in pharmaceutical industry: Productivity challenges and trends. Drug Discov. Today 2012, 17, 1088–10102.

9. Waring, M.J.; Arrowsmith, J.; Leach, A.R.; Leeson, P.D.; Mandrell, S.; Owen, R.M.; Pairaudeau, G.; Pennie, W.D.; Pickett, S.D.; Wang, J.; et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 2015, 14, 475–486

10. Basavaraj, S.; Betageri, G.V. Can formulation and drug delivery reduce attrition during drug discovery and development—Review of feasibility, benefits, and challenges. Acta Pharm. Sin. B 2014, 4, 3–17

11. . Kiriiri, G.K.; Njogu, P.M.; Mwangi, A.N. Exploring different approaches to improve the success of drug discovery and development projects: A review. Future J. Pharm. Sci. 2020, 6, 27

12. . Wang, Y.; Xing, J.; Xu, Y.; Zhou, N.; Peng, J.; Xiong, Z.; Liu, X.; Luo, X.; Luo, C.; Chen, K.; et al. In silico ADME/T modeling for rational drug design. Q. Rev. Biophys. 2015, 48, 488–515.

13. . Madden, J.C.; Enoch, S.J.; Paini, A.; Cronin, M.T.D. A Review of In Silico Tools as Alternatives to Animal Testing: Principles, Resources and Applications. Altern. Lab. Anim. 2020, 48, 146–172.

14. Van Norman, G.A. Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Part 2: Potential Alternatives to the Use of Animals in Preclinical Trials. JACC Basic Transl. Sci. 2020, 5, 387–397

15. Egan WJ, Merz KM, Baldwin JJ. Prediction of Drug Absorption Using Multivariate Statistics. J Med. Chem. 2000; 43(21):3867-3877

16. Daina Antoine, Olivier Michielin, Vincent Zoete. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness, and medicinal chemistry friendliness of small molecules. Nature - Scientific Reports. 2017; 7:42717.1-13.

17. O'Boyle NM et al. Open Babel: An open chemical toolbox. J Chem inform. 2011; 3:33.

18. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov. 2007; 6:881-90

19. Testa B, Crivori P, Reist M et al. The influence of lipophilicity on the pharmacokinetic behavior of drugs: concepts and examples. Perspect Drug Discov Des. 2000; 19:179-210.

20. Sherin Varghese, M. S. Jisha, K. C. Rajeshkumar, Virendra Gajbhiye, Niladri Haldar, Aazam Shaikh. "Molecular authentication, metabolite proling and in silico–in vitro cytotoxicity screening of endophytic Penicillium ramusculum from Withania somnifera for breast cancer therapeutics" , 3 Biotech, 2024

21. Arnott JA, Planey SL. The influence of lipophilicity in drug discovery and design. Expert Opin. Drug Discov. 2012; 7:863-875.

22. Cheng T et al. Computation of Octanol Water Partition Coefficients by Guiding an Additive Model with Knowledge. J Chem Inf. Model. 2007; 47:2140-2148.

23. Wildman SA, Crippen GM. Prediction of Physicochemical Parameters by Atomic Contributions. J Chem. Inf. Model. 1999; 39:868-873.

24. Moriguchi I, Shuichi H, Liu Q, Nakagome I, Matsushita Y. Simple Method of Calculating Octanol/Water Partition Coefficient. Chem. Pharm. Bull. 1992; 40:127-130

25. Moriguchi I, Shuichi H, Nakagome I, Hirano H. Comparison of reliability of log P values for Drugs calculated by several methods. Chem. Pharm. Bull. 1994; 42:976-978

26. Daina Antoine, Olivier Michielin, Vincent Zoete. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness, and medicinal chemistry friendliness of small molecules. Nature - Scientific Reports. 2017; 7:42717.1-13

27. Lachman LH, Lieberman, Kanig JL. The Theory and Practice of Industrial Pharmacy, Lea & Febiger, 3rd edition, 1986

28. Di LP, Artursson A, Avdeef GF, Ecker B, Faller H, Fischer JB et al. Drug Discov. Today. 2012; 17:905-912

29. Ogu CC, Maxa JL. Drug interactions due to cytochrome P450. Proc (Bayl Univ Med Cent). 2000; 13(4):421-423.

30. Ndombera FT, Maiyoh GKK, Vivian CT. Pharmacokinetic, Physicochemical and Medicinal Properties of N-Glycoside Page 2 of 8 Anti-Cancer Agent More Potent than 2-Deoxy-D-Glucose in Lung Cancer Cells. Cancer Sci Res Open Access. 2019; 6(1):1-8.

31. Baell, JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and their exclusion in bioassays. J Med. Chem. 2010; 53:2719-2740

32. Hann MM, Keseru GM. Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nature Rev. Drug Discov. 2012; 11:355-365

33. Teague S, Davis A, Leeson P, Oprea T. The Design of Leadlike Combinatorial Libraries. Angew. Chem. Int. Ed. Engl. 1999; 38:3743-3748

34. Schippmann U, Cunningham AB, Leaman DJ. Impact of cultivation and gathering of medicinal plants on biodiversity: global trends and issues. Rome: FAO, 2002, 142–167

35. Ghosh AK, Gemma S. Structure-based design of drugs and other bioactive molecules. Hoboken: John Wiley & Sons, 2015, 397–409

36. DiMasi JA, Hansen RW, Grabowsk HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003; 22:151–185.

37. Darvas F, Keseru G, Papp A, Dormán G, Urge L, Krajcsi P. In Silico and Ex, silico ADME approaches for drug discovery. Top Med Chem. 2002; 2:1287–1304

38. Hodgson J. ADMET – turning chemicals into drugs. Nat Biotechnol. 2001; 19:722–726

39. Tetko IV, Bruneau P, Mewes HW, Rohrer DC, Poda GI. Can we estimate the accuracy of ADMET predictions? Drug Discov Today. 2006; 11:700–707

40. Hansch C, Leo A, Mekapatia SB, Kurup A. QSAR and ADME. Bioorg Med Chem. 2004; 12:3391–3400

How to cite this article: Pushpak S. Bari et al. Jcpr.Human, 2024; Vol. 20 (12): 1-12.
Conflict of Interest Statement: The authors have no conflicts of interest to declare.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.